Maren Kleine-Brueggeney

Maren Kleine-Brueggeney

Auto-generated profile, based on publicly available information

Maren Kleine-Brueggeney

Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2016 in Anaesthesia
Verified
Journal Article
Closed access
PDF file
MKM. Kleine‐Brueggeney
M. Kleine‐Brueggeney
MBM. Buttenberg
M. Buttenberg
RGRobert Greif
Robert Greif
SNS. Nabecker
S. Nabecker
LTL. Theiler
L. Theiler

1 November 2021 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TPTina H. Pedersen
Tina H. Pedersen
FUFlorian Ueltschi
Florian Ueltschi
THTobias Hornshaw
Tobias Hornshaw
RGRobert Greif
Robert Greif
LTLorenz Theiler
Lorenz Theiler
MKMaren Kleine-Brueggeney
Maren Kleine-Brueggeney

2 September 2017 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
MKMaren Kleine-Brueggeney
Maren Kleine-Brueggeney
AGAnne Gottfried
Anne Gottfried
SNSabine Nabecker
Sabine Nabecker
RGRobert Greif
Robert Greif
MBMalte Book
Malte Book
LTLorenz Theiler
Lorenz Theiler
Supraglottic airway devices (SGA) are commonly used in pediatric anesthesia and serve as primary or back-up devices for difficult airway management. Most SGA are marketed without proper clinical evaluation. The purpose of this study was to evaluate the performance of the pediatric LMA Supreme™, Air-Q® and Ambu® Aura-i™. This prospective observational study was performed at Bern University Hospital, Switzerland. With ethics committee approval and a waiver for written informed consent 240 children undergoing elective surgery with an ASA class I-III and a weight of 5-30 kg were included. Three different pediatric supraglottic airway devices were assessed: The LMA Supreme™, Air-Q® and Ambu® Aura-i™. Primary outcome parameter was airway leak pressure. Secondary outcome parameters included first attempt and overall success rate, insertion time, fiberoptic view through the SGA, and adverse events. The primary hypothesis was that the mean airway leak pressure of each tested SGA was 20 cmH2O ± 10%. None of the SGA showed a mean airway leak pressure of 20 cmH2O ± 10%, but mean airway leak pressures differed significantly between devices [LMA Supreme™ 18.0 (3.4) cmH2O, Air-Q® 15.9 (3.2) cmH2O, Ambu® Aura-i™ 17.3 (3.7) cmH2O, p < 0.001]. First attempt success rates (LMA Supreme™ 100%, Air-Q® 90%, Ambu® Aura-i™ 91%, p = 0.02) and overall success rates (LMA Supreme™ 100%, Air-Q® 91%, Ambu® Aura-i™ 95%, p = 0.02) also differed significantly. Insertion times ranged from 20 (7) seconds (Air-Q®) to 24 (6) seconds (LMA Supreme™, <p = 0.005). Insertion was rated easiest with the LMA Supreme™ (very easy in 97% vs. Air-Q® 70%, Ambu® Aura-i™ 72%, p < 0.001). Fiberoptic view was similar between the SGA. Adverse events were rare. Airway leak pressures ranged from 16 to 18 cmH2O, enabling positive pressure ventilation with all successful SGA. The highest success rates were achieved by the LMA Supreme™, which was also rated easiest to insert. ClinicalTrials.gov , identifier NCT01625858 . Registered 31 May 2012.

11 October 2024 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Open access
SMSascha Meier
Sascha Meier
JBJonas Borzel
Jonas Borzel
NHNicolas Hellner
Nicolas Hellner
DCDaniel Catena
Daniel Catena
CBChristiane E. Beck
Christiane E. Beck
MKMaren Kleine-Brueggeney
Maren Kleine-Brueggeney
Enhanced recovery after surgery (ERAS) is a multimodal care pathway to enhance recovery after surgery that is well established in various surgical disciplines. In pediatric cardiac surgery, implementation of ERAS protocols remains inconsistent. We conducted a survey of active European pediatric cardiac surgical centers to assess the current state of ERAS concepts and the current practice in perioperative pediatric cardiac care. Prospective, 79-item, web-based cross-sectional survey. Web-based survey endorsed by the European Association of Cardiothoracic Anesthesiology and Intensive Care. Anesthesiologists of European pediatric cardiac surgical centers. None. Of a total of 98 centers, 50 responded. Eight responses were excluded due to incomplete survey forms or non-European location, leaving 42 responses (42.9%) for statistical analysis. Sixteen of the 42 centers (38.1%) follow an ERAS concept. Only 3 (7.1%) have formalized and detailed the ERAS concept in a written document, covering the entire perioperative period, while 13 (31%) have formalized it solely for the intraoperative period. Regarding regional and local anesthesia, 13 (31%) centers regularly practice regional anesthesia blocks, and 11 (26.2%) centers use wound infiltration by the surgical team. This European survey revealed that implementation of ERAS concepts in pediatric cardiac surgery is generally low, with considerable heterogeneity in clinical practice regarding the timing of extubation, the choice of surgical procedures triggering on-table extubation, the choice of anesthetic drugs and the use of regional anesthesia. More coordinated efforts are needed to implement ERAS concepts in pediatric cardiac surgery and harvest the benefits of ERAS concepts for the pediatric cardiac population.

27 September 2016 in Anaesthesia
Verified
Journal Article
Closed access
PDF file
MKM. Kleine‐Brueggeney
M. Kleine‐Brueggeney
RGRobert Greif
Robert Greif
NUN. Urwyler
N. Urwyler
BWB. Wirthmüller
B. Wirthmüller
LTL. Theiler
L. Theiler

1 June 2022 in Current Opinion in Anaesthesiology
Verified
Journal Article
Open access
MKMaren Kleine-Brueggeney
Maren Kleine-Brueggeney
MGMareike Grosshauser
Mareike Grosshauser
RGRobert Greif
Robert Greif
Purpose of review: Apneic oxygenation is increasingly used in pediatric anesthesia. Its benefit for specific applications depends on the effect of apneic oxygenation on safe apnea time and carbon dioxide (CO2) elimination, on differences between low and high flow oxygen delivery, and on possible adverse effects. The present review summarizes current evidence on these pathophysiological aspects of apneic oxygenation as well as its applications in pediatric anesthesia. Recent findings: Apneic oxygenation with both low flow and high flow nasal oxygen increases the safe apnea time, but does not lead to increased CO2 elimination. Airway pressures and adverse effects like atelectasis formation, oxidative stress and aerosol generation under apneic oxygenation are not well studied in pediatric anesthesia. Data from adults suggest no important effect on airway pressures when the mouth is open, and no significant formation of atelectasis, oxidative stress or aerosol generation with high flow nasal oxygen. Summary: Apneic oxygenation in pediatric anesthesia is mainly used during standard and difficult airway management. It is sometimes used for airway interventions, but CO2 accumulation remains a major limiting factor in this setting. Reports highlight the use of high flow nasal oxygen in spontaneously breathing rather than in apneic children for airway interventions.